Results 141 to 150 of about 222,217 (297)

Inherited metabolic epilepsies–established diseases, new approaches

open access: yesEpilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source

Cyclophosphamide in lupus nephritis.

open access: yes, 2005
Although not licensed for systemic lupus erythematosus (SLE), cyclophosphamide (CYC) has become over the last two decades the most widely prescribed cytotoxic drug for lupus nephritis (LN).
Houssiau, Frédéric
core  

Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei   +5 more
wiley   +1 more source

Anti‐NMDA receptor autoimmune encephalitis associated with ovarian teratoma: A case series and literature review

open access: yesInternational Journal of Gynecology &Obstetrics, Volume 169, Issue 1, Page 23-30, April 2025.
Abstract Autoimmune encephalitis is a group of disorders characterized by symptoms of dysfunction of the limbic and extra‐limbic systems that occur in association with antibodies against intracellular antigens, synapses, or proteins located on the surface of nerve cells. Anti‐NMDA (N‐methyl‐D‐aspartate) receptor encephalitis was first described in 2007
Pham Ba Nha   +6 more
wiley   +1 more source

Longitudinal AMH trajectories, ovarian reserve recovery, and fertility outcomes after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia: A real‐world cohort study

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To characterize anti‐Müllerian hormone (AMH) recovery after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia (GTN) and evaluate the impact of regimen and hysterectomy. Methods This was a retrospective cohort of 68 high‐risk GTN patients treated with EMA/CO (etoposide, methotrexate, actinomycin D ...
Wei Xue   +8 more
wiley   +1 more source

Organ‐Resolved Host Proteomic and Post‐Translational Modification Landscapes in a Mouse Model of Talaromyces marneffei Infection

open access: yesiMetaMed, EarlyView.
We presented an organ‐resolved, multiple PTM remodeling atlas of systemic T. marneffei infection, integrating quantitative proteome, phosphoproteome, ubiquitinome, acetylome, and lactylome data across the liver, lung, and spleen. The atlas delineated organ‐specific PTM signatures and a functional convergence of divergent modification types on immune ...
Wudi Wei   +16 more
wiley   +1 more source

Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen

open access: yes, 2010
Cyclophosphamide therapy may rarely cause pigmentation of the nails which is of different patterns. We report a patient who developed pigmentation of nails after six cycles of cyclophosphamide, methotrexate, and 5-flourouracil chemotherapy, each repeated
Dixit, Rakesh   +3 more
core  

Home - About - Disclaimer - Privacy